Key result
Cardiac-specific and disease-specific IgG antibodies are potential biomarkers for identifying at-risk relatives and patients who may benefit from immunosuppression or immunomodulation.
Heart-reactive autoantibodies serve as potential biomarkers to identify at-risk relatives and guide immunomodulatory therapy in patients with autoimmune myocarditis and dilated cardiomyopathy.
May identify candidates for immunomodulation in autoimmune cardiomyopathy; leaves open clinical adoption pending prospective validation.
PURPOSE OF REVIEW: Myocarditis is a clinically heterogeneous myocardial inflammatory disease, diagnosed by endomyocardial biopsy; it may be idiopathic, infectious, or autoimmune and may lead to dilated cardiomyopathy. Myocarditis and dilated cardiomyopathy represent different stages of an organ-specific autoimmune disease in genetically predisposed individuals. RECENT FINDINGS: In animal models, cell-mediated or antibody-mediated autoimmune myocarditis/dilated cardiomyopathy can be induced by viral infection or immunization with heart-specific autoantigens, or can develop spontaneously in genetically predisposed strains. Susceptibility is based on multiple major histocompatibility complex and nonmajor histocompatibility complex genes. In patients the diagnosis of autoimmune myocarditis/dilated cardiomyopathy requires exclusion of viral genome on endomyocardial biopsy and detection of serum heart-reactive autoantibodies. They are directed against multiple antigens that are found in patients and relatives from about 60% of familial and nonfamilial pedigrees. They predict dilated cardiomyopathy development among relatives, years before disease. Some antibodies have functional effects on cardiac myocytes in vitro, in animals and possibly in a dilated cardiomyopathy subset, responsive to extracorporeal immunoadsorption. SUMMARY: In myocarditis/dilated cardiomyopathy, cardiac-specific and disease-specific antibodies of IgG class are potential biomarkers for identifying 'at risk' relatives as well as those patients in whom, in the absence of active infection of the myocardium, immunosuppression, and/or immunomodulation may be beneficial. Future studies should better define the genetic basis of human autoimmune myocarditis/dilated cardiomyopathy.
No takes yet. Share an insight, caveat, or question.
Caforio et al. (2008) conducted a review in Myocarditis and dilated cardiomyopathy. Cardiac-specific and disease-specific IgG antibodies are potential biomarkers for identifying at-risk relatives and patients who may benefit from immunosuppression or immunomodulation.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: